MX2020007177A - Cristales. - Google Patents

Cristales.

Info

Publication number
MX2020007177A
MX2020007177A MX2020007177A MX2020007177A MX2020007177A MX 2020007177 A MX2020007177 A MX 2020007177A MX 2020007177 A MX2020007177 A MX 2020007177A MX 2020007177 A MX2020007177 A MX 2020007177A MX 2020007177 A MX2020007177 A MX 2020007177A
Authority
MX
Mexico
Prior art keywords
degrees
sup
compound
cukî
radiation
Prior art date
Application number
MX2020007177A
Other languages
English (en)
Inventor
Toshio Fujiwara
Kusalakumari Sukumar Senthil Kumar
Joanna Bis
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2020007177A publication Critical patent/MX2020007177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un objeto principal de la presente invención es proporcionar nuevos cristales de (S)-N2-[1-(4-fluorofenil)etil]-4-(1-metil-1H-p irazol-4-il)-N6-(pirazin-2-il)piridina-2,6-diamina maleato (en lo sucesivo, referido como el ''compuesto A"). Un cristal de Forma-l del compuesto A, que muestra picos de difracción en su espectro de difracción de polvo de rayos-X en al menos los siguientes ángulos de difracción 2?: 6.9 grados, 9.4 grados, 12.5 grados, 15.1 grados, 16.4 grados, 18.3 grados, 19.0 grados, 24.9 grados, 25.4 grados, 27.3 grados, y 27.7 grados, en donde espectro de difracción de polvo de rayos-X se obtiene al utilizar radiación Cu Ka (?=1 .54Å). Un cristal de Forma-II del compuesto A, que muestra picos de difracción en su espectro de difracción de polvo de rayos-X en al menos los siguientes ángulos de difracción 2?: 6.9 grados, 9.2 grados, 12.4 grados, 14.8 grados, 16.5 grados, 18.1 grados, 18.5 grados, 19.8 grados, 23.6 grados, 24.9 grados, y 27.7 grados, en donde espectro de difracción de polvo de rayos-X se obtiene al utilizar radiación Cu Ka (?=1.54Å).
MX2020007177A 2017-09-28 2018-09-27 Cristales. MX2020007177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017187297 2017-09-28
PCT/JP2018/035830 WO2019065793A1 (ja) 2017-09-28 2018-09-27 結晶

Publications (1)

Publication Number Publication Date
MX2020007177A true MX2020007177A (es) 2020-10-14

Family

ID=65901897

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007177A MX2020007177A (es) 2017-09-28 2018-09-27 Cristales.
MX2023005387A MX2023005387A (es) 2017-09-28 2020-07-13 Cristales de maleato de forma-ii de (s)-n2-[1-(4-fluorofenil)etil] -4-(1-metil-1h-pirazol-4-il)-n6-(pirazin-2-il)piridina-2,6-diamin a.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023005387A MX2023005387A (es) 2017-09-28 2020-07-13 Cristales de maleato de forma-ii de (s)-n2-[1-(4-fluorofenil)etil] -4-(1-metil-1h-pirazol-4-il)-n6-(pirazin-2-il)piridina-2,6-diamin a.

Country Status (12)

Country Link
US (1) US11680055B2 (es)
EP (1) EP3689862A4 (es)
JP (2) JPWO2019065793A1 (es)
KR (2) KR20230142814A (es)
CN (2) CN111132971A (es)
AU (2) AU2018338857B2 (es)
BR (1) BR112020005847A2 (es)
CA (1) CA3076803A1 (es)
MX (2) MX2020007177A (es)
PH (1) PH12020550139A1 (es)
RU (1) RU2020114659A (es)
WO (1) WO2019065793A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022239068A1 (ja) * 2021-05-10 2022-11-17 日本新薬株式会社 サイトカインストーム抑制剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2453474T3 (es) 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Derivados de aminopirazina y medicamento correspondiente
JPWO2012005299A1 (ja) 2010-07-07 2013-09-05 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
JP5668756B2 (ja) 2010-08-11 2015-02-12 日本新薬株式会社 悪性リンパ腫治療剤
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物

Also Published As

Publication number Publication date
RU2020114659A (ru) 2021-10-28
JP2023105140A (ja) 2023-07-28
WO2019065793A1 (ja) 2019-04-04
CN116874467A (zh) 2023-10-13
KR20200060418A (ko) 2020-05-29
EP3689862A4 (en) 2021-01-27
JPWO2019065793A1 (ja) 2020-10-22
RU2020114659A3 (es) 2022-04-08
AU2018338857A1 (en) 2020-04-16
CA3076803A1 (en) 2019-04-04
CN111132971A (zh) 2020-05-08
BR112020005847A2 (pt) 2020-09-29
US11680055B2 (en) 2023-06-20
KR20230142814A (ko) 2023-10-11
US20200223823A1 (en) 2020-07-16
EP3689862A1 (en) 2020-08-05
MX2023005387A (es) 2023-05-23
AU2018338857B2 (en) 2023-05-25
AU2023203547A1 (en) 2023-07-06
PH12020550139A1 (en) 2020-12-07

Similar Documents

Publication Publication Date Title
MX2020009957A (es) Compuestos para el tratamiento de enfermedad de hungtinton.
MX2020014098A (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington.
MY186531A (en) Crystals
MY175373A (en) Crystal form of phenylamino pyrimidine derivatives
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
TN2009000459A1 (en) Metabolites of (thio) carbamoyl-cyclohexane derivatives
MX2022015558A (es) Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino ) pirimidin-4-il) benzamida.
MX2023004668A (es) Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico.
UY35275A (es) Derivados de aminopirazina
MX2023005387A (es) Cristales de maleato de forma-ii de (s)-n2-[1-(4-fluorofenil)etil] -4-(1-metil-1h-pirazol-4-il)-n6-(pirazin-2-il)piridina-2,6-diamin a.
WO2018044767A3 (en) Aminopyrimidines as alk inhibitors
JO2747B1 (en) Vehicles
EA201590250A1 (ru) Производные карбамат/мочевины
AU2018272088A8 (en) Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
PH12021550374A1 (en) Small molecule menin inhibitors
PH12020551841A1 (en) Stable pharmaceutical formulation
SG11201809127PA (en) Crystalline polymorph of 15b-hydroxy-osaterone acetate
MX2021014104A (es) Formas cristalinas de 5-bromo-2,6-di(1 h-pirazol-1-il)pirimidin-4- amina y nuevas sales.
CO6270221A2 (es) "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea".
MX2020007881A (es) Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3- carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopr opil)-amida.
MX2020011070A (es) Formas cristalinas de un compuesto.
EA202192903A1 (ru) Кристаллическая форма ингибитора plk4
EA202190009A1 (ru) Производные бензимидазола и их применение в качестве ингибиторов idh1
AU2018337153A1 (en) Crystalline sulfamide compound